logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10155990 B1

PDFFull Text
Date of Patent:
Dec. 18, 2018

Filed:

Jun. 19, 2014

Method for predicting therapeutic efficacy of pi3k/akt/mtor inhibitor on basis of phlda1 or pik3c2b expression

Applicant:

Taiho Pharmaceutical Co., Ltd., Chiyoda-ku, Tokyo, JP;

Inventors:

Tetsuya Abe, Tsukuba, JP;

Hiraku Itakdani, Tsukuba, JP;

Assignee:

Taiho Pharmaceuticals, Inc., Tokyo, JP;

Attorney:

Rothwell, Figg, Ernst & Manbeck, P.C.

Primary Examiner:

Nizal S Chandrakumar

Int. Cl.
CPC ...
A61K 31/366 (2006.01); C12Q 1/6886 (2018.01); A61K 31/5365 (2006.01); G01N 33/574 (2006.01); A61K 31/436 (2006.01); A61K 31/4155 (2006.01); A61K 31/519 (2006.01); A61K 31/52 (2006.01); A61K 31/5377 (2006.01); A61K 31/7064 (2006.01); A61K 31/4375 (2006.01); A61K 31/4745 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); A61K 31/366 (2013.01); A61K 31/4155 (2013.01); A61K 31/436 (2013.01); A61K 31/4375 (2013.01); A61K 31/4745 (2013.01); A61K 31/519 (2013.01); A61K 31/52 (2013.01); A61K 31/5365 (2013.01); A61K 31/5377 (2013.01); A61K 31/7064 (2013.01); G01N 33/57484 (2013.01); G01N 33/57496 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/4703 (2013.01); G01N 2333/91215 (2013.01); G01N 2800/52 (2013.01);
Abstract

An object of the present invention is to provide a chemotherapy using a PI3K/AKT/mTOR inhibitor that produces an excellent antitumor effect on a cancer patient. The present invention provides a method for predicting the therapeutic efficacy of the chemotherapy using the antitumor agent comprising a PI3K/AKT/mTOR inhibitor on a cancer patient on the basis of the expression level of PHLDA1 and/or PIK3C2B in a biological sample containing tumor cells isolated from the cancer patient.

Find Patent Forward Citations

Abe, Tetsuya. (2018). Method for predicting therapeutic efficacy of pi3k/akt/mtor inhibitor on basis of phlda1 or pik3c2b expression (U.S. Patent No. 10155990). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/10155990

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…